Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor
Recruiting
N/A
Interventional Study
Cystic Fibrosis (CF)
Mucoviscidosis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Health Services Research
- Participants needed
- 130 (estimated)
- Sponsor
- University Hospital, Lille · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Cystic fibrosis is a genetic disorder affecting the entire body and associated with respiratory exacerbations, impaired quality of life and reduced life expectancy. The therapeutic management of cystic fibrosis has been profoundly changed by the recent arrival of a combination of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators, Elexacaftor-Tezacaftor-Ivacafto…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Male or female
* Adult aged 18 or over
* Suffering from cystic fibrosis
* Treated at the CRCM in Lille and Créteil
* Treated by ETI
* Be covered by social security
* Be able to understand the requirements of the study, provide written informed consent, and comply with the stud…
Contacts